Research Analysts Set Expectations for Omnicell Q4 Earnings

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Stock analysts at Zacks Research lifted their Q4 2024 EPS estimates for Omnicell in a note issued to investors on Thursday, January 2nd. Zacks Research analyst R. Department now forecasts that the company will earn $0.29 per share for the quarter, up from their prior estimate of $0.28. The consensus estimate for Omnicell's current full-year earnings is $0.93 per share. Zacks Research also issued estimates for Omnicell's Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.19 EPS and FY2026 earnings at $1.01 EPS.

A number of other brokerages have also recently issued reports on OMCL. JPMorgan Chase & Co. upped their price target on shares of Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. Bank of America dropped their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research note on Monday. StockNews.com downgraded shares of Omnicell from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Wells Fargo & Company boosted their price objective on shares of Omnicell from $30.00 to $41.00 and gave the stock an "equal weight" rating in a report on Monday, October 14th. Finally, Benchmark reiterated a "buy" rating and set a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Omnicell has an average rating of "Hold" and a consensus price target of $50.17.

Omnicell Stock Down 1.3 %

Shares of NASDAQ OMCL traded down $0.61 during trading on Monday, reaching $44.71. The company had a trading volume of 365,558 shares, compared to its average volume of 275,119. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.74. The business's 50-day moving average is $46.17 and its 200 day moving average is $40.65. The stock has a market cap of $2.07 billion, a PE ratio of -114.64, a P/E/G ratio of 34.96 and a beta of 0.78.

Insider Buying and Selling

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.64% of the stock is owned by insiders.

Institutional Trading of Omnicell

A number of hedge funds and other institutional investors have recently modified their holdings of OMCL. Rhumbline Advisers boosted its holdings in Omnicell by 3.0% in the 2nd quarter. Rhumbline Advisers now owns 147,188 shares of the company's stock worth $3,984,000 after buying an additional 4,281 shares during the period. Arizona State Retirement System grew its position in shares of Omnicell by 2.9% during the second quarter. Arizona State Retirement System now owns 12,853 shares of the company's stock worth $348,000 after purchasing an additional 357 shares in the last quarter. Headlands Technologies LLC bought a new stake in Omnicell during the 2nd quarter valued at approximately $104,000. Federated Hermes Inc. lifted its holdings in Omnicell by 1,113.6% in the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company's stock worth $26,830,000 after purchasing an additional 909,480 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Omnicell by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company's stock worth $31,955,000 after purchasing an additional 3,570 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.